COMMUNIQUÉS West-GlobeNewswire

-
Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection
17/12/2018 -
Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2019.
17/12/2018 -
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
17/12/2018 -
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
17/12/2018 -
TG Therapeutics, Inc. and Dana-Farber Cancer Institute Announce Publication of Clinical Data from the Phase 1/1b Trial of Umbralisib in Combination with Ibrutinib in Lancet Haematology
17/12/2018 -
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
17/12/2018 -
Dova Pharmaceuticals Announces Management Changes
17/12/2018 -
Loop Industries Appoints Sidney Horn to Board of Directors
17/12/2018 -
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
17/12/2018 -
Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis
17/12/2018 -
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
17/12/2018 -
Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial
17/12/2018 -
FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)
17/12/2018 -
Blood donors needed to help patients this holiday season
17/12/2018 -
Les donneurs de sang encouragés à prendre rendez-vous pour aider les patients pendant les Fêtes
17/12/2018 -
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
17/12/2018 -
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
17/12/2018 -
Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
17/12/2018 -
TRU NIAGEN® Expands North American Footprint with Product Launch in Canada
17/12/2018
Pages